Abstract
Arterial hypertension is a disease that still affects a major part of the population worldwide, and leads to fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. From the CDC statistical analysis, as regarding to United States, 1 of every 3 adults has high blood pressure, and οnly about half (54%) of them have it under control. Furthermore, all that leads to a nation cost about $46 billion each year. Efforts to find new ways to regulate arterial hypertension are therefore imperative.
In our days, a lot of references have been made to the use of a new therapeutic combination, that of azilsartan – an innovative ARB, in combination with chlorthalidone. Ιn fact, it is a combination now prescribed in a number of countries.
A significant number of trials shows both azilsartan vs popular antihypertensive drugs, as well as chlorthalidone vs chlorothiazide, to present a better antihypertensive effect. This effect is even greater when the two substances are combined. In this article, we will try to present the latest findings concerning the efficacy, safety and clinical utility of this combination, as well as its adverse events, in comparison with other widely used therapeutic options.
Keywords: Azilsartan medoxomil, chlorthalidone, combination, hypertension, stroke, myocardial infarction.
Graphical Abstract
33
5